A phase 2 study of capecitabine (R340) in patients who have failed previous treatment with taxane for metastatic breast cancer.
Phase 2
- Conditions
- breast cancer
- Registration Number
- JPRN-jRCT2080220019
- Lead Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- Female
- Target Recruitment
- Not specified
Inclusion Criteria
1. Females
2. 20 and over Age and below 75
3. performance status 0-2,
4. Patients with a history of at least one regimen of chemotherapy including taxene (paclitaxel or docetaxel) (including (neo-) adjuvant therapy)
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method objective response rate, time to response, duration of response, time to disease progression, overall survival, response rate stratified by previous treatment, safety profile
- Secondary Outcome Measures
Name Time Method